8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T15141 | DM4 | Ravtansine | Others , Microtubule Associated |
DM4 (Ravtansine) can be used in the preparation of antibody drug conjugate and it is an antitubulin agent. It can inhibit cell division. | |||
T77907 | Tusamitamab ravtansine | HuMAb2-3-SPDB-DM4,SAR-408701 | |
Tusamitamab ravtansine (SAR-408701) is a DM4-linked anti-CEACAM5 antibody-drug conjugate (ADC) comprising a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) conj... | |||
T76940 | Cantuzumab ravtansine | ||
Cantuzumab ravtansine (IMGN242; huC242-DM4), an antibody-drug conjugate (ADC), consists of the humanized monoclonal antibody huC242 covalently bonded through a disulfide linkage to the cytotoxic agent DM4 (DM4). This com... | |||
T77825 | Mirvetuximab soravtansine | IMGN853 | |
Mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate (ADC), integrates the cytotoxic agent DM4 with the humanized monoclonal antibody M9346A through a covalent bond. This compound targets folate receptor 1 (FO... | |||
T77122 | Praluzatamab | Others | |
Praluzatamab is a monoclonal antibody targeting an activated white blood cell adhesion molecule (ALCAM/CD116). Praluzatamab is a naked antibody to Praluzatamab ravtansine and can be used to synthesize antibody active mol... | |||
T77748 | Tusamitamab | Others | |
Tusamitamab is an IgG1 monoclonal antibody targeting CEACAM5 and is the naked antibody to Tusamitamab ravtansine.Tusamitamab can be used to synthesize the antibody-activator coupling Tusamitamab ravtansine. | |||
T76857 | Anetumab | Others | |
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-activated molecule coupling, Anetumab ravtansine.Anetumab can ... | |||
T77911 | Cantuzumab | ||
Cantuzumab, a monoclonal antibody, binds to the CanAg antigen and is commonly conjugated with various cytotoxic agents to form antibody-drug conjugates (ADCs), including Cantuzumab mertansine and Cantuzumab ravtansine [1... |